Expert Opinions and Perspectives in Recent Advances in Tuberculosis Vaccine Development—BCG and Beyond
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 261
Special Issue Editors
Interests: innate and adaptive immunity; innate lymphoid cells; vaccine induced immunity; infectious diseases; cardiac diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tuberculosis is one of the leading causes of death due to a single infectious agent. Even with the development of standard drug regimens and century-old vaccines (bacille Calmette Guerin, BCG) in place, the global impact of the tuberculosis epidemic is increasing. Novel and effective vaccine(s) are crucial to end the epidemic. Although BCG vaccine is effective in preventing childhood pulmonary tuberculosis, it has variable efficacy is adults. Therefore, efforts have been made by the World Health Organization, as well as the various TB researchers, to develop better alternatives to decrease the risk of tuberculosis. In this Special Issue, we would like to discuss about the most recent advances in the field of TB vaccine research, which will include advanced studies in BCG vaccine mechanism, the bottleneck towards developing better vaccines and potential new vaccines.
Dr. Shibali Das
Dr. Nargis Khan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis
- BCG
- M72
- adjuvants
- clinical trials
- animal models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
